Clinical trials: Drug
Alzheimer Disease, Healthy Volunteers
Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants
The purpose of this study was to assess the safety, tolerability, and pharmacokinetic (PK) of TAK-071 when administered as single rising dose (SRD) and multiple rising dose (MRD) orally in healthy participants and participants…
- Trial name
- NCT02769065
- Testing
- TAK-071, Donepezil
- Where
- United States
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- Takeda
Diabetic Macular Edema
Chart Review: Drug Utilization Study in Participants Who Received Ozurdex™ (Dexamethasone Intravitreal Implant) 0.7 mg Injections for Visual Impairment Due to Diabetic Macular Edema (DME)
A retrospective, non-interventional, observational, multi-center, drug utilization study to be conducted in adult participants with visual impairment due to DME treated with Ozurdex implants in Germany and Switzerland from 1…
- Trial name
- NCT03889444
- Testing
- Dexamethasone intravitreal implant
- Where
- United States
- Volunteers
- 141 people
- Sponsor
- Allergan
Hepatitis C, Chronic
Directly Observed Therapy for HCV in Chennai, India
The primary objective of this pilot trial is to evaluate the feasibility of 12 weeks vs. 24 weeks of field-based directly observed therapy (DOT) for HCV therapy in a resource-limited setting.
- Trial name
- C-DOT (NCT02541409)
- Testing
- Sofosbuvir, Pegylated Interferon alfa-2a, Ribavirin
- Where
- India
- Volunteers
- 50 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Hepatitis, HIV/AIDS
Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV
Background: Standard treatment for the hepatitis C virus (HCV) is a combination of the drugs peg-IFN and ribavirin. However, this treatment is not very effective in people with a serious type of HCV (HCV genotype 1) and also in…
- Trial name
- NCT01443923
- Testing
- Boceprevir, Peg-Interferon-alfa 2B, Ribavirin
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pancreatic Cancer
Individualized Drug Treatment for Treating Patients With Pancreatic Cancer
RATIONALE: Treating tumor tissue in the laboratory with different drugs may help doctors find the best drug for treating individual patients with pancreatic cancer.
- Trial name
- NCT00276744
- Testing
- cetuximab, capecitabine, docetaxel
- Where
- United States
- Volunteers
- 249 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Nasal Polyps
Anti-Inflammatory Agent in Sinusitis
To evaluate the efficacy of an anti-inflammatory agent compared with placebo in relieving signs and symptoms of disease in patients with sinusitis.
- Trial name
- E1416 (NCT02874144)
- Testing
- AZ compound, Collection of Biological Specimens, Intranasal corticosteroid
- Volunteers
- 43 people
- Sponsor
- Northwestern University
Open-Angle Glaucoma, Ocular Hypertension
Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension
This study will evaluate the safety and efficacy of new ophthalmic formulations of bimatoprost in patients with open angle glaucoma and ocular hypertension.
- Trial name
- NCT01157364
- Testing
- bimatoprost 20 µg generation 2, bimatoprost 15 µg generation 2, bimatoprost 10 µg generation 2
- Where
- 57 sites in United States, Australia and 8 more
- Volunteers
- 109 people
- Sponsor
- Allergan
Depression, Melancholia
Antidepressant Treatment of Melancholia in Late Life
The purpose of this study is to compare the safety and effectiveness of a select serotonin re-uptake inhibitor (SSRI, sertraline) and a tricyclic antidepressant (TCA, nortriptyline) in outpatients over the age of 60 who have…
- Trial name
- NCT00000378
- Testing
- Sertraline, Nortriptyline
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- New York State Psychiatric Institute
Hepatocellular Carcinoma
A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib
This is a Phase 3 multicenter, randomized study evaluating the safety and efficacy of ramucirumab DP plus BSC as a double-blind, placebo-controlled (placebo plus BSC) comparison.
- Trial name
- REACH (NCT01140347)
- Testing
- Ramucirumab DP (IMC-1121B), BSC
- Where
- 146 sites in United States, Australia and 25 more
- Volunteers
- 565 people
- Sponsor
- Eli Lilly and Company
Pulmonary Disease, Chronic Obstructive
Study of Safety and Drug Levels of CCI15106 Inhalation Powder in Healthy Adults and Adults With Moderate Chronic Obstructive Pulmonary Disease. Study of CCI15106 Levels in People Standing Near the Person Inhaling the Drug
This single and repeat increasing dose study will collect information on safety, tolerability and drug levels in the body of the CCI15106 inhalation powder.
- Trial name
- NCT03235726
- Testing
- CCI15106
- Where
- United Kingdom
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Short Bowel Syndrome
A Study of Teduglutide in Japanese Children With Short Bowel Syndrome Aged 4 Months or Older
The main aims of the study are to check for side effects from teduglutide. Participants will receive a daily injection of teduglutide just under the skin (subcutaneous) for 24 weeks. Then they are followed up for another 4 weeks.
- Trial name
- NCT05027308
- Testing
- Teduglutide
- Where
- 6 sites in Japan
- Volunteers
- 3 people
- Sponsor
- Takeda
Peripheral Artery Disease, Hypertension
Comparison of 2 Beta Blocker Drugs on Peripheral Arterial Disease in Patients With High Blood Pressure
This is a 26-week, prospective double-blind, randomized pilot trial of nebivolol versus an active control, metoprolol succinate, in patients with established lower-extremity peripheral artery disease, hypertension, and at least…
- Trial name
- ENCOMPASS (NCT01499134)
- Testing
- nebivolol, Metoprolol succinate
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Thomas Jefferson University
Chronic Hepatitis c, Cirrhosis, Liver
Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment
The HALT-C Trial is a National Institute of Diabetes and Digestive and Kidney Diseases sponsored, randomized clinical trial of long-term use of Peginterferon alfa-2a (pegylated interferon) in patients who failed to respond to…
- Conditions
- Chronic Hepatitis c, Cirrhosis, Liver, Fibrosis, Liver, Hepatic Cirrhosis
- Trial name
- HALT-C (NCT00006164)
- Testing
- Peginterferon alfa-2a + Ribavirin, Peginterferon alfa-2a
- Where
- 11 sites in United States
- Volunteers
- 1,050 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Hereditary Angioedema (HAE)
Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese Volunteers
This is a single-dose study to evaluate the pharmacokinetics, safety, and tolerability of icatibant administered to adult Japanese subjects.
- Trial name
- NCT02045264
- Testing
- Icatibant (30 mg)
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Shire
Alcoholism, Alcohol Abuse
Dutasteride for the Reduction of Alcohol Use in Male Drinkers
The purpose of this study is to evaluate whether dutasteride is safe and effective for reducing alcohol use in male drinkers who want to stop or reduce their drinking.
- Conditions
- Alcoholism, Alcohol Abuse, Alcohol Dependence
- Trial name
- NCT01262287
- Testing
- Dutasteride
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- UConn Health
Healthy
Pharmacodynamic Study of Cilostazol in Healthy Volunteers
The primary objective of this study is to investigate the effects of Cilostazol, Acetylsalycylic acid and Clopidogrel alone as well as combinations of Cilostazol/Acetylsalicylic acid and Cilostazol/ Clopidogrel on ex-vivo…
- Trial name
- CiloMecT (NCT02554721)
- Testing
- Cilostazol, Acetylsalicylic acid, Clopidogrel
- Where
- Germany
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Seasonal Allergic Conjunctivitis
Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination in Adults With Seasonal Allergic Conjunctivitis
To evaluate the efficacy of Combo compared to its individual components and compared to vehicle in a population of subjects with seasonal allergic conjunctivitis.
- Trial name
- NCT05591755
- Testing
- Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution, Ketotifen fumarate ophthalmic solution 0.035%, Brimonidine tartrate ophthalmic solution 0.025%
- Where
- 6 sites in United States
- Volunteers
- 229 people
- Sponsor
- Bausch & Lomb Incorporated
Acute Lymphoid Leukemia, Acute Myeloid Leukemia
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
This is an open-label, multicenter, phase 2 clinical trial to evaluate the antitumor activity of brentuximab vedotin as a single agent in patients with CD30-positive nonlymphomatous malignancies.
- Conditions
- Acute Lymphoid Leukemia, Acute Myeloid Leukemia, Anemia, Refractory, With Excess of Blasts, Solid Tumors
- Trial name
- NCT01461538
- Testing
- brentuximab vedotin
- Where
- 29 sites in United States
- Volunteers
- 84 people
- Sponsor
- Seagen Inc.
Marijuana Dependence
Nicotine Patch for Marijuana Withdrawal
The purpose of this 3-year trial is to test the efficacy of transdermal nicotine patch versus placebo patch on marijuana withdrawal symptoms in cannabis-dependent individuals, using a randomized, double-blind, and…
- Trial name
- NMW (NCT01400243)
- Testing
- Nicotine
- Where
- United States
- Volunteers
- 127 people
- Sponsor
- Southern Illinois University Carbondale
Rheumatoid Arthritis
A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) With an Inadequate Response or Intolerance to Biologic DMARDs
The study objective of Period 1 (Day 1 to Week 24) is to compare the safety and efficacy of upadacitinib 30 mg once daily (QD) and 15 mg QD versus placebo for the treatment of signs and symptoms of participants with moderately to…
- Trial name
- SELECT-BEYOND (NCT02706847)
- Testing
- Upadacitinib
- Where
- 188 sites in United States, Australia and 25 more
- Volunteers
- 499 people
- Sponsor
- AbbVie
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.